Mon Sep 09 14:48:09 UTC 2024: ## Lunit’s AI Technology Integrated into Roche’s Digital Pathology Platform for Cancer Research
**SEOUL, South Korea -** Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced its collaboration with Roche to integrate its Lunit SCOPE PD-L1 22C3 TPS into Roche’s navify® Digital Pathology platform. This marks the first deployment of Lunit’s AI technology with Roche, aiming to enhance tools for cancer research and precision medicine.
Lunit SCOPE PD-L1 is an AI-powered tool that automates the analysis of the PD-L1 tumor proportion score (TPS), a crucial biomarker in cancer immunotherapy. By providing more accurate and efficient assessments, the tool aims to improve the accuracy of PD-L1 scoring, a notoriously challenging process.
The collaboration, initially launched in the US, will expand to Canada, the EU (UK), Korea, and Japan, showcasing a commitment to improving cancer diagnostics and treatment across global healthcare markets.
“We’re thrilled to work together with Roche within its open digital pathology ecosystem,” said Brandon Suh, CEO of Lunit. “This collaboration is a significant step towards making Lunit’s AI tools accessible globally. We aim to accelerate the advancement of precision medicine by enhancing workflow efficiency and introducing new biomarkers for improved patient care.”
Lunit SCOPE PD-L1 TPS is currently available for research use only and is not intended for diagnostic procedures.
This partnership between Lunit and Roche highlights the growing role of AI in advancing cancer research and development. By providing pathologists and scientists with powerful new tools, the collaboration is poised to significantly impact the fight against cancer.
First Piper 